FDA Rules, Exosomes and Stem Cell Scams

This hub collects what has been written here about how orthobiologics are regulated in the United States, and about the marketing that runs ahead of it. It is for the patient offered a stem cell injection out of a bottle, an exosome injection, ozone therapy or a peptide, and for the physician who wants the source documents. Posts here run from 2017 to 2026, so check the date on anything you rely on.

Two federal categories, and why the difference matters

Human cells and tissue products fall under 21 CFR Part 1271. A product can be distributed as section 361 tissue without premarket approval only if it is minimally manipulated and used for the same basic function it had in the donor, which the regulations call homologous use. Everything else is a section 351 biologic drug, which needs a license or an active investigational exemption before it reaches a patient.

In 2019 the FDA stated that using umbilical cord blood for orthopedic conditions is not homologous use under 21 CFR 1271.3(c), and its CBER division told a physician who asked that every Wharton's jelly product then on the US market was an unregistered biologic drug. In a statement issued on June 3, 2021, the agency grouped stem cells, adipose SVF, umbilical cord blood, amniotic fluid, Wharton's jelly and exosomes together as biologic drugs rather than section 361 tissue. Bone marrow used in orthopedics sits on the other side of that line, which is a regulatory fact rather than an endorsement; the FDA endorses no stem cell source.

Registered, permitted and approved are three different things

Those three words get used interchangeably, and that is where most patient confusion starts. Registering a tissue product is a listing step that one post here documents as taking about 45 minutes, and it says nothing about whether the product is safe or works. An investigational new drug permit lets a company study a product under FDA oversight; it is not permission to sell it. Institutional review board approval is a study level ethics review and does not exempt a clinic from federal drug rules. A clinic that answers with the words FDA registered, or says its procedure is allowed because a study is running, has not answered what you asked.

What the FDA has done, and what it has not

Enforcement is real but uneven. The agency sent a warning letter to US Stem Cell and its chief scientific officer in August 2017 over adipose SVF, and in June 2019 a federal court affirmed the injunction against that company. Untitled letters have gone to sellers of birth tissue and exosome products, including RichSource Stem Cells in 2019 and the R3 Stem Cell network, and five more went out during 2024, all of them posted publicly by the agency.

What the agency has not done matters as much. It has not approved any exosome product for any medical condition, it has not approved any ozone device or ozone therapy for any condition, and there is no FDA certified stem cell pain cream. Because a letter does not always pull a product from the market, courts and state regulators have carried part of the load, from at least nine civil suits by mid 2018 to the New York Attorney General's 2019 case against Park Avenue Stem Cell over adipose SVF.

Where the picture has changed

Some of what is listed below has aged, and saying so is more useful than pretending otherwise. In December 2020, Peter Marks of CBER was asked at an AAOM meeting whether a clinician could put adipose SVF or microfat into a knee joint or a tendon, and the answer was no, in what was presented as unofficial guidance. A September 2024 randomized trial in Arthroscopy, following 75 knee osteoarthritis patients for a year, is discussed here as evidence for microfat and as a compliant way to use adipose tissue here. Note each date. Peptides move faster still: the 2026 post on BPC-157, TB-500, GHK-Cu and compounding pharmacy limits supersedes anything older here. Florida Senate Bill 1768, introduced in 2025, would have let clinics use unapproved stem cell products in orthopedics without FDA approval; it was covered here as proposed legislation in conflict with federal law, and its current status is worth checking.

What can legally be used, and how to check

In a US orthopedic practice, the products on solid regulatory ground come from the patient. Platelet rich plasma prepared from your own blood is not treated as a drug or an HCT/P, and it can be advertised for orthopedic conditions when the claims rest on accepted medical evidence. Bone marrow taken from your own body is the source this practice uses and the one with published human orthopedic outcomes behind it. Before booking, find the physician's full name, degree and specialty training on the site, ask what the product is and whether it is FDA approved for the condition being treated, and walk away from any clinic advertising orthopedics alongside autism, cerebral palsy and heart failure. The evidence is covered in the PRP, bone marrow concentrate and research hubs.